New Study Links HRT to Lower Dementia Risk — But Timing Is Key

Hormone replacement therapy has been used for decades to help women manage symptoms of menopause. But whether it could also influence what happens to the brain years later has been much harder to answer.

Now, a large new study suggests the relationship may depend heavily on who takes HRT and when they start.

Researchers analyzed data from more than 183,000 postmenopausal women in the UK and followed them for an average of 13 years. Women who had used HRT were about 10% less likely to develop dementia overall and 16% less likely to develop Alzheimer’s disease than women who had never used it.

But those averages only tell part of the story.

The association was considerably stronger in some groups. Women who had undergone surgical menopause and used HRT had a 26% lower risk of dementia than non-users, while women with naturally lower lifetime estrogen exposure also appeared to benefit more. Genetics mattered too, and the age at which women started treatment appeared to influence the results.

The findings don’t prove that hormone therapy prevents dementia. But they add to growing evidence that the relationship between menopause, estrogen and brain health may be more complicated than simply asking whether HRT is “good” or “bad.” Instead, timing, genetics and a woman’s individual menopause history may all be important pieces of the puzzle.

What the study found – and what it didn’t

A 2026 study published in Alzheimer’s & Dementia tracked 183,450 postmenopausal women from the UK Biobank over a combined 2.43 million person-years of follow-up, during which 3,948 cases of dementia were diagnosed. In this observational analysis, HRT use – defined as at least one year of treatment – was associated with a 10% lower risk of all-cause dementia overall, with stronger associations seen in women who had surgical menopause, APOE ε4 carriers, and women with lower lifetime estrogen exposure.

The observational analysis also found that the association between HRT use and dementia risk varied by dementia subtype, with stronger associations seen for Alzheimer’s disease than for other forms of dementia. Researchers found no significant association between HRT use and non-Alzheimer’s forms of dementia.

The study authors themselves noted that evidence on the link between HRT use and cognitive outcomes had been “conflicting and inconclusive.” This was an observational study, meaning it tracked what happened to women who chose to use HRT versus those who didn’t – it was not a randomized controlled trial, where women would be randomly assigned to treatment or placebo. Women who take HRT may differ from non-users in ways that independently affect dementia risk: their overall health, their access to healthcare, their socioeconomic circumstances. Researchers accounted for factors including age, socioeconomic background, and other health conditions – but residual differences between HRT users and non-users could still contribute to the results.

Why surgical menopause changes the math

The onset of the menopausal transition often coincides with the preclinical phase of dementia, while surgically induced menopause has been linked with increased lifetime dementia risk. The biological reason comes down to the speed of hormonal change. Natural menopause involves a gradual decline in estrogen over several years. The higher female prevalence of dementia is thought to be related to the effects of menopause on brain metabolism and the impact of the APOE4 gene variant being greater in women.

Surgical menopause, by contrast, is abrupt. When both ovaries are removed, estrogen levels fall sharply almost overnight – a physiological shock that appears to create a different kind of brain vulnerability. In the UK Biobank analysis, women who had undergone surgical menopause showed the greatest apparent benefit from HRT, with a 26% lower risk of all-cause dementia compared with non-users.

The study also found that women who had naturally lower lifetime estrogen exposure – due to starting their periods late or experiencing early menopause – appeared to benefit more from HRT, with a 16% lower risk of any type of dementia. Women who had abundant estrogen exposure through their reproductive years and then experienced a gradual natural decline may have less hormonal ground to recover.

Researchers noted that “hormone therapy’s effects on brain health are complex and influenced by individual biological factors.” The study identifies subgroups – it does not identify a universal benefit.

The critical window: timing is everything

The strongest single predictor of whether HRT was associated with lower dementia risk wasn’t the type of menopause or the woman’s genetics. It was when she started treatment.

Initiation of HRT in women aged 46 to 56 was associated with a 10% reduced risk of dementia – but that association was not observed in women who began HRT after age 56. This finding fits with what’s become known as the “critical window” hypothesis – the idea that the brain has a finite period of sensitivity to estrogen after menopause, and that treatment started within that window may behave very differently than treatment started years later.

Postmenopausal women show accelerated cognitive decline, greater brain atrophy, and reduced brain glucose metabolism compared with age-matched men – a disparity increasingly linked to the hormonal transition of menopause. Estrogen receptors in the brain play a role in maintaining mood, memory, and cognition.

A 2025 mini review in Frontiers in Molecular Biosciences concluded that the brain may retain estrogen sensitivity during a finite period after menopause – and beyond that window, estrogen receptors may downregulate, potentially leaving the brain in a more vulnerable, pro-inflammatory state. Starting HRT after that window has closed may do little to protect cognition, and could in some contexts be counterproductive.

The WHIMS trial, published in JAMA, found that estrogen plus progestin therapy increased the risk of probable dementia in postmenopausal women aged 65 and older. Participants were already at least 65 when they entered the study, meaning many were well past the typical age of menopause. This distinction later became important as researchers explored whether the timing of hormone therapy might influence its effects on the brain.

Type of menopause, timing, and hormonal history are each inseparable from the outcome in this body of research.

The APOE4 question

The higher female prevalence of dementia is partly thought to be related to the impact of the genetic risk factor APOE4 being greater in women than in men. APOE4 is a variant of the apolipoprotein E gene, involved in how the body processes fats and clears certain proteins from the brain. According to the National Institute on Aging, APOE4 is the strongest known genetic risk factor for Alzheimer’s disease, though carrying the variant doesn’t mean a person will definitely develop the disease. Roughly 25% of people carry one copy of APOE4, and 2 to 3% carry two copies.

In the UK Biobank study, the association between HRT use and lower dementia risk was stronger in women who carry the APOE4 variant. APOE4 carriers showed a 13% lower dementia risk with HRT use. That is a modest figure, and again reflects an association rather than a proven protective mechanism. The finding raises the question of whether genetic screening might one day inform decisions about hormone therapy timing – a direction some researchers are beginning to explore.

The regulatory shift and what it reflects

The regulatory context around HRT changed significantly in late 2025. In November 2025, the FDA requested labeling changes for hormone therapy products – specifically removing longstanding black-box warnings that had appeared on HRT products since the early 2000s- to better reflect the current understanding of benefits and risks. The decision reflected growing scientific recognition that the WHIMS findings applied to a specific demographic – older postmenopausal women – and should not have been applied as broadly as they were.

Research published in Physiological Reviews found that estrogen facilitates higher cognitive functions by acting on brain regions including the prefrontal cortex and hippocampus – areas most involved in memory and executive function. When estrogen drops at menopause, those regions begin adapting to the new hormonal environment. The critical window hypothesis suggests that early replacement may preserve some of that adaptation in a more favorable direction, while late replacement may interfere with adaptations already underway.

For women who’ve experienced menopause symptoms affecting their mood, memory, or cognition, this evolving science adds context worth discussing with a prescribing clinician – not as a reason to start HRT specifically for brain protection, but as part of a fuller picture of what HRT does and when.

Read More: 8 Surprising Things You Didn’t Know About Menopause

What this means for you

The UK Biobank study doesn’t change the current guidance: HRT is used primarily to treat menopausal symptoms, not as a strategy for preventing dementia. Because this was an observational study, it cannot prove that hormone therapy itself was responsible for the lower dementia rates researchers observed. Other differences between women who did and didn’t use HRT could have contributed to the results.

What the findings do suggest is that timing and individual circumstances may matter. The association with lower dementia risk was strongest when HRT was started around the typical menopausal transition, particularly between ages 46 and 56. Women who experienced surgical menopause or had fewer years of natural estrogen exposure also appeared to show stronger associations.

Professor Anne-Marie Minihane of the University of East Anglia’s Norwich Medical School, who led the research, explained: “While HRT has long been prescribed primarily to relieve menopausal symptoms such as hot flushes and night sweats, this work suggests it may also play a role in long-term cognitive health for some women.”

For women already considering HRT for symptoms such as hot flashes, night sweats, or sleep disruption, the study adds another piece of information to a decision that is already highly individual. It isn’t a reason to start hormone therapy solely to prevent dementia, but it does strengthen the case for looking at HRT through a more personalized lens, taking into account a woman’s age, menopause history, health risks, and when treatment begins.

Disclaimer: This information is not intended to be a substitute for professional medical advice, diagnosis, or treatment and is for information only. Always seek the advice of your physician or another qualified health provider with any questions about your medical condition and/or current medication. Do not disregard professional medical advice or delay seeking advice or treatment because of something you have read here.

AI Disclaimer: This article was created with the assistance of AI tools and reviewed by a human editor.